# US 2026/0285927 A1 · Antimicrobial peptides with alpha-core helices

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0285927 A1
- Document ID: US20260285927A1
- Status: Published application
- Kind: A1
- Application number: 19/555,705
- Filed: 2026-03-03
- Published: 2026-09-24
- Earliest claimed: 2017-05-11
- Assignees: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Applicants: Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center
- Inventors: Nannette Y. Yount; Michael R. Yeaman
- Web page: https://patentgrep.com/patent/US20260285927A1

## CPC

- A61P 31/04: Antibacterial agents
- C07K 14/4723: {Cationic antimicrobial peptides, e.g. defensins}
- C07K 7/08: having 12 to 20 amino acids (gastrins C07K14/595; somatostatins C07K14/655; melanotropins C07K14/68)
- C07K 14/00: Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K 14/43518: {from spiders}
- C07K 14/43522: {from scorpions}
- C07K 14/43563: {from insects}
- C07K 14/43568: {from wasps}
- C07K 14/43572: {from bees}
- C07K 14/43581: {from Drosophila}
- C07K 14/46: from vertebrates
- C07K 14/463: {from amphibians}
- C07K 14/465: from birds
- G16B 15/20: Protein or domain folding
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2319/00: Fusion polypeptide
- Y02A 50/30: Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- G16B: BIOINFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR GENETIC OR PROTEIN-RELATED DATA PROCESSING IN COMPUTATIONAL MOLECULAR BIOLOGY
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y02A: TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE

## Abstract

Computational systems and methods are described for identifying new α-helical antimicrobial peptides using a systemic consensus formula. Newly identified α-helical antimicrobial peptides are tested experimentally and show potent microbiocidal activities.

## Claims

### Claim 1

A method for treating an infection in a patient in need thereof, comprising administering to the patient a peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1-14 and sequences derived from anyone of SEQ ID NO: 1-14 with one amino acid substitution, wherein the peptide is not longer than 60 amino acid residues in length.

### Claim 2 (depends on 1)

The method of claim 1, wherein the peptide is not longer than 50 amino acid residues in length.

### Claim 3 (depends on 1)

The method of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO:8.

### Claim 4 (depends on 1)

The method of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO:1.

### Claim 5 (depends on 1)

The method of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO:6.

### Claim 6 (depends on 1)

The method of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO:7.

### Claim 7 (depends on 1)

The method of claim 1, wherein the peptide comprises the amino acid sequence of SEQ ID NO:10.

### Claim 8 (depends on 1)

The method of claim 1, further comprising administering to the patient an antimicrobial agent.

### Claim 9 (depends on 8)

The method of claim 8, wherein the antimicrobial agent is selected from the group consisting of imipenem, ceftazidime, colistin, chloroquine, artemisinin, vancomycin and daptomycin.

### Claim 10 (depends on 1)

The method of claim 1, wherein the infection is caused by a Gram-negative bacterium, a Gram-positive bacterium or a fungus.

### Claim 11 (depends on 1)

The method of claim 1, wherein the administration is subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional, or intracranial injection, or infusion.

### Claim 12

A computer-implemented method of identifying a peptide having antimicrobial activity, comprising:
identifying a consensus formula from aligned amino acid sequences known to have an antimicrobial activity;
tuning the consensus formula with a test search against a plurality of proteins with known antimicrobial activity; and
searching in a protein database, with one or more processors, for amino acid fragments matching the consensus formula, wherein the search takes as input one or more criteria selected from the group consisting of location of the fragment in a protein, size of the protein, organism of the protein, and signal peptide of the protein.

### Claim 13 (depends on 12)

The method of claim 12, wherein the tuning comprising shortening the length of the consensus formula or changing substation options at one or more amino acid residues.

### Claim 14

A computer-implemented method of identifying an α-helical antimicrobial peptide, comprising:
searching in a protein database, with one or more processors, for amino acid fragments matching a consensus formula:
X-[VILMCFWYAG]-[KRHEDNQSTAG]-[KRHEDNQSTAG]-[VILMCFWYAG]-[VILMCFWYAG]-[KRHEDNQSTAG]-[KRHEDNQSTAG]-[VILMCFWYAG]-X-[KRHEDNQSTAG]-[VILMCFWYAG], wherein X denotes any amino acid residue;
filtering the searched fragments based on presence of a signal peptide in the respective protein; and
evaluating the searched fragments for one or more criteria selected from the group consisting of:
hydrophobic moment;
mean hydrophobicity;
net charge;
frequencies or ratio of K and R; and
isoelectric point.
